Solid Biosciences (SLDB) Equity Ratio (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Equity Ratio for 8 consecutive years, with 0.79 as the latest value for Q3 2024.
- Quarterly Equity Ratio rose 0.9% to 0.79 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.79 through Sep 2024, up 0.9% year-over-year, with the annual reading at 0.77 for FY2023, 5.71% down from the prior year.
- Equity Ratio hit 0.79 in Q3 2024 for Solid Biosciences, down from 0.84 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.9 in Q3 2021 to a low of 0.55 in Q3 2020.
- Historically, Equity Ratio has averaged 0.8 across 5 years, with a median of 0.8 in 2023.
- Biggest five-year swings in Equity Ratio: crashed 33.81% in 2020 and later soared 63.5% in 2021.
- Year by year, Equity Ratio stood at 0.77 in 2020, then rose by 16.11% to 0.9 in 2021, then fell by 9.23% to 0.81 in 2022, then decreased by 5.71% to 0.77 in 2023, then grew by 2.82% to 0.79 in 2024.
- Business Quant data shows Equity Ratio for SLDB at 0.79 in Q3 2024, 0.84 in Q2 2024, and 0.85 in Q1 2024.